BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 33544421)

  • 1. Prioritizing the worries of AML patients: Quantifying patient experience using best-worst scaling.
    Richardson DR; Oakes AH; Crossnohere NL; Rathsmill G; Reinhart C; O'Donoghue B; Bridges JFP
    Psychooncology; 2021 Jul; 30(7):1104-1111. PubMed ID: 33544421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developing and piloting an instrument to prioritize the worries of patients with acute myeloid leukemia.
    Bridges JF; Oakes AH; Reinhart CA; Voyard E; O'Donoghue B
    Patient Prefer Adherence; 2018; 12():647-655. PubMed ID: 29731612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Developing an instrument to assess patient preferences for benefits and risks of treating acute myeloid leukemia to promote patient-focused drug development.
    Seo J; Smith BD; Estey E; Voyard E; O' Donoghue B; Bridges JFP
    Curr Med Res Opin; 2018 Dec; 34(12):2031-2039. PubMed ID: 29565196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using Social Media to Uncover Treatment Experiences and Decisions in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Who Are Ineligible for Intensive Chemotherapy: Patient-Centric Qualitative Data Analysis.
    Booth A; Bell T; Halhol S; Pan S; Welch V; Merinopoulou E; Lambrelli D; Cox A
    J Med Internet Res; 2019 Nov; 21(11):e14285. PubMed ID: 31755871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient and caregiver preferences for the potential benefits and risks of a seizure forecasting device: A best-worst scaling.
    Janse SA; Dumanis SB; Huwig T; Hyman S; Fureman BE; Bridges JFP
    Epilepsy Behav; 2019 Jul; 96():183-191. PubMed ID: 31150998
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age at Diagnosis and Patient Preferences for Treatment Outcomes in AML: A Discrete Choice Experiment to Explore Meaningful Benefits.
    Richardson DR; Crossnohere NL; Seo J; Estey E; O'Donoghue B; Smith BD; Bridges JFP
    Cancer Epidemiol Biomarkers Prev; 2020 May; 29(5):942-948. PubMed ID: 32132149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy.
    Peay HL; Hollin I; Fischer R; Bridges JF
    Clin Ther; 2014 May; 36(5):624-37. PubMed ID: 24852596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-centered communication tool for older patients with acute myeloid leukemia, their caregivers, and oncologists: A single-arm pilot study.
    LoCastro M; Sanapala C; Wang Y; Jensen-Battaglia M; Wittink M; Norton S; Klepin HD; Richardson DR; Mendler JH; Liesveld J; Huselton E; O'Dwyer K; Cortes AM; Rodriguez C; Dale W; Loh KP
    Cancer Med; 2023 Apr; 12(7):8581-8593. PubMed ID: 36533397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best-Worst Scaling to Prioritize Outcomes Meaningful to Caregivers of Youth with Mental Health Multimorbidities: A Pilot Study.
    Camelo Castillo W; Ross M; Tariq S; dosReis S
    J Dev Behav Pediatr; 2018; 39(2):101-108. PubMed ID: 29461997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caregiver preferences for emerging duchenne muscular dystrophy treatments: a comparison of best-worst scaling and conjoint analysis.
    Hollin IL; Peay HL; Bridges JF
    Patient; 2015 Feb; 8(1):19-27. PubMed ID: 25523316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caregiver priorities for endpoints to evaluate treatments for Prader-Willi syndrome: a best-worst scaling.
    Tsai JH; Scheimann AO; McCandless SE; Strong TV; Bridges JFP
    J Med Econ; 2018 Dec; 21(12):1230-1237. PubMed ID: 30256699
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Integrated Palliative and Oncology Care for Patients With Acute Myeloid Leukemia: A Randomized Clinical Trial.
    El-Jawahri A; LeBlanc TW; Kavanaugh A; Webb JA; Jackson VA; Campbell TC; O'Connor N; Luger SM; Gafford E; Gustin J; Bhatnagar B; Walker AR; Fathi AT; Brunner AM; Hobbs GS; Nicholson S; Davis D; Addis H; Vaughn D; Horick N; Greer JA; Temel JS
    JAMA Oncol; 2021 Feb; 7(2):238-245. PubMed ID: 33331857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side effects from acute myeloid leukemia treatment: results from a national survey.
    Crossnohere NL; Richardson DR; Reinhart C; O'Donoghue B; Love SM; Smith BD; Bridges JFP
    Curr Med Res Opin; 2019 Nov; 35(11):1965-1970. PubMed ID: 31188058
    [No Abstract]   [Full Text] [Related]  

  • 14. Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom.
    Castejón N; Cappelleri JC; Cuervo J; Lang K; Mehta P; Mokgokong R; Mamolo C
    Health Qual Life Outcomes; 2018 Apr; 16(1):66. PubMed ID: 29669568
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and validation of the AML-QOL: a quality of life instrument for patients with acute myeloid leukemia.
    Buckley SA; Halpern AB; Othus M; Jimenez-Sahagun D; Walter RB; Lee SJ
    Leuk Lymphoma; 2020 May; 61(5):1158-1167. PubMed ID: 31909637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.
    Marshall M; Crowther R; Almaraz-Serrano A; Creed F; Sledge W; Kluiter H; Roberts C; Hill E; Wiersma D; Bond GR; Huxley P; Tyrer P
    Health Technol Assess; 2001; 5(21):1-75. PubMed ID: 11532238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prioritizing Parental Worry Associated with Duchenne Muscular Dystrophy Using Best-Worst Scaling.
    Peay HL; Hollin IL; Bridges JF
    J Genet Couns; 2016 Apr; 25(2):305-13. PubMed ID: 26289228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Psychosocial interventions for informal caregivers of people living with cancer.
    Treanor CJ; Santin O; Prue G; Coleman H; Cardwell CR; O'Halloran P; Donnelly M
    Cochrane Database Syst Rev; 2019 Jun; 6(6):CD009912. PubMed ID: 31204791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A best-worst scaling experiment to identify patient-centered claims-based outcomes for evaluation of pediatric antipsychotic monitoring programs.
    Mackie TI; Kovacs KM; Simmel C; Crystal S; Neese-Todd S; Akincigil A
    Health Serv Res; 2021 Jun; 56(3):418-431. PubMed ID: 33369739
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.